We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Under the Inflation Reduction Act of 2022 (IRA), signed into law by President Joe Biden in August 2022, the federal government capped prescription drug cost inflation and is negotiating drug ...

The donut hole was a gap in Medicare Part D prescription drug coverage that occurred between the initial stage and catastrophic stage of coverage. In 2025, new rules under the Inflation Reduction ...

According to CMS data, Medicare Part D spending on Ozempic was more than $4.6 billion in 2022. Ozempic has become emblematic of the explosive enthusiasm for GLP-1 medications in the U.S. Danish ...

In one of its last actions, the Biden administration released the next 15 drugs selected for Medicare negotiation and the blockbuster diabetes drug Ozempic will be among those bargained for this year.

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...

WASHINGTON — Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated directly between the government and drug manufacturers ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...